These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18171306)

  • 1. Measuring acceptable treatment failure rates for community-acquired pneumonia: potential for reducing duration of treatment and antimicrobial resistance.
    Kaye KS; Harris AD; McDonald JR; Strausbaugh LJ; Perencevich E;
    Infect Control Hosp Epidemiol; 2008 Feb; 29(2):137-42. PubMed ID: 18171306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicians' acceptable treatment failure rates in antibiotic therapy for coagulase-negative staphylococcal catheter-associated bacteremia: implications for reducing treatment duration.
    Perencevich EN; Harris AD; Kaye KS; Bradham DD; Fisman DN; Liedtke LA; Strausbaugh LJ;
    Clin Infect Dis; 2005 Dec; 41(12):1734-41. PubMed ID: 16288397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
    Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
    J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How long should we treat community-acquired pneumonia?
    Scalera NM; File TM
    Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: a survey of infectious diseases consultants.
    Perencevich EN; Kaye KS; Strausbaugh LJ; Fisman DN; Harris AD;
    Clin Infect Dis; 2004 Feb; 38(4):476-82. PubMed ID: 14765338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-pronged process improvement gets great buy-in from physicians.
    Data Strateg Benchmarks; 2001 Feb; 5(2):24-7, 17. PubMed ID: 11255787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy for ambulatory infectious pneumonia].
    Stollewerk D
    Pneumologie; 2008 Dec; 62(12):744; author reply 744. PubMed ID: 19051156
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of community acquired pneumonia].
    Drömann D; Schaaf B
    Pneumologie; 2008 Jul; 62(7):411-9; quiz 420-2. PubMed ID: 18609462
    [No Abstract]   [Full Text] [Related]  

  • 11. Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors.
    Schouten JA; Hulscher ME; Kullberg BJ; Cox A; Gyssens IC; van der Meer JW; Grol RP
    J Antimicrob Chemother; 2005 Sep; 56(3):575-82. PubMed ID: 16049096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of processes and outcomes of pneumonia care between hospitalists and community-based primary care physicians.
    Rifkin WD; Conner D; Silver A; Eichorn A
    Mayo Clin Proc; 2002 Oct; 77(10):1053-8. PubMed ID: 12374249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of antimicrobial guidelines for community-acquired pneumonia in children.
    Smith MJ; Kong M; Cambon A; Woods CR
    Pediatrics; 2012 May; 129(5):e1326-33. PubMed ID: 22492769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Questionnaire survey of guideline implementation for community acquired pneumonia with retrospective analysis of the empiric treatment in 490 patients].
    Xu ZJ; Ding K; Huang H; Sun TY; Ke HX; Tong ZH; Wei TN; Peng K; Yao B; Li FX; Liu JH; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):442-6. PubMed ID: 17673019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
    Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
    J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic prescribing for CAP in Mexico.
    Guerrero-Zarraga C; Nava-Ocampo AA
    Fam Med; 2003 Jun; 35(6):387. PubMed ID: 12817857
    [No Abstract]   [Full Text] [Related]  

  • 17. [Diagnosis and ambulatory treatment of patients with community-acquired pneumonia: variability of complementary tests and study of the effectiveness of roxithromycin. Study Group on Ambulatory Treatment of Community-Acquired Pneumonia (NACTA)].
    Rev Clin Esp; 1999 Nov; 199(11):700-4. PubMed ID: 10638232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
    Echols RM; Tillotson GS; Song JX; Tosiello RL
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
    Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
    Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.